Total Payments
$382,075
2024 Payments
$740.25
Companies
37
Transactions
784
Medicare Patients
4,995
Medicare Billing
$281,264
Payment Breakdown by Category
Other$326,756 (85.5%)
Travel$21,172 (5.5%)
Consulting$20,330 (5.3%)
Food & Beverage$13,789 (3.6%)
Education$27.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $326,756 | 101 | 85.5% |
| Travel and Lodging | $21,172 | 94 | 5.5% |
| Consulting Fee | $20,330 | 21 | 5.3% |
| Food and Beverage | $13,789 | 564 | 3.6% |
| Education | $27.66 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $247,240 | 142 | $0 (2022) |
| Amgen Inc. | $64,873 | 102 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $43,248 | 148 | $0 (2024) |
| PFIZER INC. | $17,338 | 75 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,738 | 67 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,169 | 80 | $0 (2024) |
| Aralez Pharmaceuticals US Inc. | $719.31 | 4 | $0 (2017) |
| Boston Scientific Corporation | $361.60 | 18 | $0 (2023) |
| Amarin Pharma Inc. | $302.22 | 18 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $281.56 | 20 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $740.25 | 46 | PFIZER INC. ($189.49) |
| 2023 | $545.47 | 28 | Novartis Pharmaceuticals Corporation ($79.78) |
| 2022 | $70,934 | 32 | Novo Nordisk Inc ($70,934) |
| 2021 | $99,585 | 140 | Novo Nordisk Inc ($95,404) |
| 2020 | $24,247 | 60 | Novo Nordisk Inc ($15,721) |
| 2019 | $45,997 | 147 | Amgen Inc. ($25,570) |
| 2018 | $79,661 | 156 | Novo Nordisk Inc ($48,013) |
| 2017 | $60,366 | 175 | Novartis Pharmaceuticals Corporation ($28,089) |
All Payment Transactions
784 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Kestra Medical Technology Services, Inc. | Assure WCD (Device) | Food and Beverage | Cash or cash equivalent | $31.66 | General |
| Category: Cardiology | ||||||
| 12/06/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $19.84 | General |
| Category: Coronary | ||||||
| 11/22/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $16.63 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $37.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Cardiology | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $10.71 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/23/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/12/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $11.20 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/20/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Cardiology | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/11/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/07/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.49 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/28/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $24.32 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 08/27/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $4.85 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/14/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/02/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/26/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 07/17/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $7.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 707 | 834 | $230,586 | $54,933 |
| 2022 | 17 | 1,150 | 1,277 | $220,749 | $62,307 |
| 2021 | 13 | 1,629 | 2,047 | $319,884 | $75,022 |
| 2020 | 15 | 1,509 | 1,943 | $375,564 | $89,003 |
Total Patients
4,995
Total Services
6,101
Medicare Billing
$281,264
Procedure Codes
61
All Medicare Procedures & Services
61 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 178 | 258 | $96,778 | $24,019 | 24.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 128 | 128 | $74,550 | $17,191 | 23.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 89 | 89 | $43,544 | $9,964 | 22.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 195 | 233 | $9,995 | $2,378 | 23.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 20 | 21 | $1,575 | $416.01 | 26.4% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 50 | 57 | $1,500 | $293.28 | 19.6% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Facility | 2023 | 14 | 14 | $952.00 | $239.88 | 25.2% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Facility | 2023 | 12 | 12 | $900.00 | $237.72 | 26.4% |
| 93246 | Heart rhythm recording of continous external ekg over 8-15 days | Office | 2023 | 21 | 22 | $792.00 | $194.00 | 24.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 269 | 275 | $56,100 | $13,605 | 24.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 56 | 59 | $34,338 | $8,485 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 86 | 101 | $21,614 | $6,961 | 32.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 39 | 39 | $11,427 | $3,894 | 34.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 43 | 68 | $11,220 | $3,677 | 32.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 40 | $9,440 | $3,133 | 33.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 36 | $9,684 | $3,124 | 32.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $7,750 | $2,598 | 33.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 41 | 41 | $6,806 | $2,198 | 32.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $6,426 | $2,124 | 33.1% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2022 | 40 | 58 | $6,264 | $2,035 | 32.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $4,836 | $1,616 | 33.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 29 | 34 | $5,032 | $1,587 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 19 | 24 | $4,608 | $1,542 | 33.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 19 | 19 | $4,370 | $1,473 | 33.7% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2022 | 73 | 73 | $5,256 | $1,293 | 24.6% |
About Dr. Mark Greathouse, MD
Dr. Mark Greathouse, MD is a Cardiovascular Disease healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093796542.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Greathouse, MD has received a total of $382,075 in payments from pharmaceutical and medical device companies, with $740.25 received in 2024. These payments were reported across 784 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($326,756).
As a Medicare-enrolled provider, Greathouse has provided services to 4,995 Medicare beneficiaries, totaling 6,101 services with total Medicare billing of $281,264. Data is available for 4 years (2020–2023), covering 61 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Pittsburgh, PA
- Active Since 11/10/2005
- Last Updated 01/20/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1093796542
Products in Payments
- Ozempic (Drug) $178,649
- Repatha (Biological) $64,486
- ENTRESTO (Drug) $40,405
- Victoza (Drug) $21,804
- ELIQUIS (Drug) $21,534
- Rybelsus (Drug) $14,311
- RYBELSUS (Drug) $12,533
- Tresiba (Drug) $8,130
- XARELTO (Drug) $1,169
- ZONTIVITY (Drug) $705.72
- Corlanor (Drug) $386.61
- Vascepa (Drug) $302.22
- CHANTIX (Drug) $287.47
- LifeVest (Device) $250.01
- LEQVIO (Drug) $226.08
- BRILINTA (Drug) $196.88
- VERQUVO (Drug) $148.74
- BYSTOLIC (Drug) $144.30
- EMBLEM (Device) $132.02
- FARXIGA (Drug) $113.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Pittsburgh
Dr. John Chenarides, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Dr. George Gabriel, Do, DO
Cardiovascular Disease — Payments: $801,111
Cardiovascular Disease $801,111
Andrew Pogozelski, M.d, M.D
Cardiovascular Disease — Payments: $442,274
Cardiovascular Disease $442,274
Ramzi Khalil, Md, MD
Cardiovascular Disease — Payments: $281,654
Cardiovascular Disease $281,654
David Lasorda, Do, DO
Cardiovascular Disease — Payments: $278,090
Cardiovascular Disease $278,090
Dr. Nathan Estes, M.d, M.D
Cardiovascular Disease — Payments: $146,656
Cardiovascular Disease $146,656